Early prostate specific antigen response and overall survival in metastatic hormone sensitive prostate cancer: Real-world data on age, body mass index, and treatment.

作者
Vaidehi Panchal,J. B. Gruber,Carley Pickett,Sumrah Khan,Jasnoor Malhotra,Jason M. Doherty,Daniel B. Eaton,Martin William Schoen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (7_suppl): 109-109
标识
DOI:10.1200/jco.2026.44.7_suppl.109
摘要

109 Background: Prostate-specific antigen (PSA) response is a strong prognostic marker for overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC), as shown in prospective trials. A rapid, deep PSA drop (≤0.2 ng/mL within 6 months) is linked to improved survival, but real-world evidence remains limited. This study examines real-world patterns of early PSA response and its prognostic significance in mHSPC, considering age, body mass index (BMI), and treatment. Methods: Retrospective cohort study of 5,048 U.S. Veterans with mHSPC using Veterans Health Administration data between 2017–2024. Early PSA response was defined as PSA ≤0.2 ng/mL at 6–12 months. OS and PSA response heterogeneity were analyzed by age, BMI, and treatment type (androgen deprivation therapy (ADT) alone, ADT+docetaxel, or ADT+androgen receptor pathway inhibitor (ARPI)). Kaplan–Meier and Cox proportional hazards models evaluated OS while chi-squared tests compared clinical characteristics. Results: Of 5,048 veterans with mHSPC, 2,572 received ADT monotherapy, 511 received ADT+docetaxel, and 1,961 received ADT+ARPI. PSA ≤0.2 ng/mL at 6–12 months was achieved in 30% of patients on ADT monotherapy, 36% with docetaxel-based therapy, and 53% on ADT+ARPI (p<0.001). Higher BMI was associated with greater PSA response rates—29% for BMI<25, 42% for BMI 25–29.9, and 47% for BMI≥30 (p = 0.001). No consistent trend was observed between age and PSA response. Kaplan–Meier analysis demonstrated improved OS for patients achieving PSA ≤ 0.2 ng/mL, regardless of age, BMI, or treatment group. Median survival (MS) by early PSA response was as follows: for PSA ≤0.2 ng/mL (n=1,982), MS was not reached due to >50% survival at 60 months; for PSA 0.2–2 ng/mL (n=1,302), MS was 52 months (ADT), 45 months (ADT+docetaxel), and 44.5 months (ARPI); for PSA 2–10 ng/mL (n=808), MS was 30 months (ADT), 32 months (ADT+docetaxel), and 25 months (ARPI); and for PSA >10 ng/mL (n=952), MS was 20 months (ADT), 22 months (ADT+docetaxel), and 16 months (ARPI). Conclusions: PSA decline to ≤0.2 ng/mL at 6–12 months was a strong predictor of OS regardless of treatment. Combination therapy with ADT+ARPI led to a more robust PSA response rates and better survival. These real-world results are consistent with clinical trial evidence, further supporting the prognostic value of early PSA kinetics as a surrogate marker for survival and clinical outcomes. Hazard model. PSA Threshold Categories Median Survival (months) Adjusted HR* 95% CI P-Value ≤0.2 NR* ref -- -- -- >0.2 to 2.0 48 1.95 1.75 2.17 <0.001 2.0 to 10 29 3.24 2.89 3.63 <0.001 10+ 19 5.76 5.17 6.42 <0.001 *NR = not reached; HR = hazard ratio.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Master完成签到 ,获得积分10
2秒前
肖肖完成签到 ,获得积分10
4秒前
4秒前
7秒前
抗体药物偶联完成签到,获得积分10
9秒前
多边形完成签到 ,获得积分10
10秒前
blh完成签到 ,获得积分10
11秒前
李大拿完成签到 ,获得积分10
11秒前
墨林云海完成签到,获得积分10
12秒前
12秒前
烂漫的煎饼完成签到 ,获得积分0
13秒前
flyinthesky完成签到,获得积分10
14秒前
那就发个呆完成签到,获得积分10
15秒前
伊登发布了新的文献求助10
15秒前
clorox3完成签到,获得积分10
16秒前
Clorox2完成签到,获得积分10
16秒前
waveless完成签到,获得积分10
16秒前
Clorox完成签到,获得积分10
17秒前
hui完成签到 ,获得积分10
18秒前
难过果汁完成签到,获得积分10
18秒前
20秒前
何一非完成签到,获得积分10
20秒前
hzw83完成签到,获得积分10
23秒前
HC完成签到,获得积分10
24秒前
马喽完成签到,获得积分10
26秒前
小白完成签到 ,获得积分10
29秒前
微笑的夏山完成签到 ,获得积分10
32秒前
嗷嗷嗷什完成签到 ,获得积分10
33秒前
汉堡包的应助被伊登采纳,获得10
33秒前
xmingpsy完成签到,获得积分10
33秒前
eeven完成签到 ,获得积分10
33秒前
禾伙人完成签到,获得积分10
34秒前
张晓祁完成签到,获得积分0
34秒前
偏偏完成签到 ,获得积分10
36秒前
老辈子莫搞完成签到,获得积分10
37秒前
39秒前
赘婿的应助被马喽采纳,获得10
39秒前
恬恬完成签到 ,获得积分10
43秒前
跳跃完成签到,获得积分10
44秒前
yueying完成签到,获得积分0
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173347
求助须知:如何正确求助?哪些是违规求助? 9565632
关于积分的说明 21780648
捐赠科研通 7767505
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555841
邀请新用户注册赠送积分活动 2476749